Nykode Therapeutics AS (OSL:NYKD)
Norway · Delayed Price · Currency is NOK 1.742
-0.084 (-4.60%)
Aug 1, 2025, 4:25 PM CET
Nykode Therapeutics AS Company Description
Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases.
The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer.
Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.
Nykode Therapeutics AS
| Country | Norway |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Michael Engsig |
Contact Details
Address: Oslo Research Park Oslo, 0349 Norway | |
| Phone | 47 22 95 81 93 |
| Website | nykode.com |
Stock Details
| Ticker Symbol | NYKD |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | NO0010714785 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael Thyring Engsig | Chief Executive Officer |
| Dr. Agnete B. Fredriksen Ph.D. | Co-Founder and Chief Scientific Officer |
| Harald Gurvin | Chief Financial Officer |
| Ulrich Blaschke | Chief Technology Officer |
| Louise Stubbe | Chief Legal Officer |